|
1
|
Amorosi EL and Ultmann JE: Thrombotic
thrombocytopenic purpura: Report of 16 cases and review of the
literature. Medicine. 45:139–159. 1966. View Article : Google Scholar
|
|
2
|
Allford SL, Hunt BJ, Rose P and Machin SJ:
Haemostasis and Thrombosis Task Force, British Committee for
Standards in Haematology: Guidelines on the diagnosis and
management of the thrombotic microangiopathic haemolytic anaemias.
Br J Haematol. 120:556–573. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Said A, Haddad RY, Stein R and Lerma EV:
Thrombotic thrombocytopenic purpura. Dis Mon. 60:500–504. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edel E, Al-Ali HK, Seeger S, Kauschat D
and Matthes G: efficacy and safety profile of solvent/detergent
plasma in the treatment of acute thrombotic thrombocytopenic
purpura: A single-center experience. Transfus Med Hemother.
37:13–19. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ye YF, Wang YS and Shen ZY: National Guide
to Clinical Laboratory Procedures. Third. Southeast University
Press; Nanjing: 2006
|
|
6
|
Rovner BW and Folstein MF: Mini-mental
state exam in clinical practice. Hosp Pract (Off Ed).
22:991031061101987.PubMed/NCBI
|
|
7
|
Chalmers J: The 1999 WHO-ISH guidelines
for the management of hypertension. Med J Aust. 171:458–459.
1999.PubMed/NCBI
|
|
8
|
Bell WR, Braine HG, Ness PM and Kickler
TS: Improved survival in thrombotic thrombocytopenic
purpura-hemolytic uremic syndrome. Clinical experience in 108
patients. N Engl J Med. 325:398–403. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
George JN: How I treat patients with
thrombotic thrombocytopenic purpura: 2010. Blood. 116:4060–4069.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bukowski RM, Hewlett JS, Harris JW,
Hoffman GC, Battle JD Jr, Silverblatt E and Yang IY: Exchange
transfusions in the treatment of thrombotic thrombocytopenic
purpura. Semin Hematol. 13:219–232. 1976.PubMed/NCBI
|
|
11
|
Fontana S, Hovinga JA Kremer, Lämmle B and
Taleghani B Mansouri: Treatment of thrombotic thrombocytopenic
purpura. Vox Sang. 90:245–254. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rizzo C, Rizzo S, Scirè E, Di Bona D,
Ingrassia C, Franco G, Bono R, Quintini G and Caruso C: Thrombotic
thrombocytopenic purpura: A review of the literature in the light
of our experience with plasma exchange. Blood Transfus. 10:521–532.
2012.PubMed/NCBI
|
|
13
|
Westwood JP, Webster H, McGuckin S,
McDonald V, Machin SJ and Scully M: Rituximab for thrombotic
thrombocytopenic purpura: Benefit of early administration during
acute episodes and use of prophylaxis to prevent relapse. J Thromb
Haemost. 11:481–490. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Heidel F, Lipka DB, von Auer C, Huber C,
Scharrer I and Hess G: Addition of rituximab to standard therapy
improves response rate and progression-free survival in relapsed or
refractory thrombotic thrombocytopenic purpura and autoimmune
haemolytic anaemia. Thromb Haemost. 97:228–233. 2007.PubMed/NCBI
|
|
15
|
Foley SR, Webert K, Arnold DM, Rock GA,
Clark WF, Barth D and Sutton DM; Members of the Canada Apheresis
Group (CAG), : A Canadian phase II study evaluating the efficacy of
rituximab in the management of patients with relapsed/refractory
thrombotic thrombocytopenic purpura. Kidney Int Suppl. S55–S58.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tun NM and Villani GM: Efficacy of
rituximab in acute refractory or chronic relapsing non-familial
idiopathic thrombotic thrombocytopenic purpura: A systematic review
with pooled data analysis. J Thromb Thrombolysis. 34:347–359. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moake JL, Rudy CK, Troll JH, Weinstein MJ,
Colannino NM, Azocar J, Seder RH, Hong SL and Deykin D: Unusually
large plasma factor VIII: Von willebrand factor multimers in
chronic relapsing thrombotic thrombocytopenic purpura. N Engl J
Med. 307:1432–1435. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Furlan M, Robles R and Lämmle B: Partial
purification and characterization of a protease from human plasma
cleaving von willebrand factor to fragments produced by in vivo
proteolysis. Blood. 87:4223–4234. 1996.PubMed/NCBI
|
|
19
|
Gerritsen HE, Robles R, Lämmle B and
Furlan M: Partial amino acid sequence of purified von willebrand
factor-cleaving protease. Blood. 98:1654–1661. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hovinga JA Kremer and Lämmle B: Role of
ADAMTS13 in the pathogenesis, diagnosis, and treatment of
thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ
Program. 2012:610–616. 2012.PubMed/NCBI
|
|
21
|
Duraković N, Radonić R and Gasparović V:
Thrombotic thrombocytopenic purpura-the role of ADAMTS13 assay in
clinical practice. Coll Antropol. 34:1087–1091. 2010.PubMed/NCBI
|
|
22
|
Hovinga JA Kremer, Vesely SK, Terrell DR,
Lämmle B and George JN: Survival and relapse in patients with
thrombotic thrombocytopenic purpura. Blood. 115:1500–1511. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peyvandi F, Lavoretano S, Palla R, Feys
HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT,
Fabris F, Zver S, et al: ADAMTS13 and anti-ADAMTS13 antibodies as
markers for recurrence of acquired thrombotic thrombocytopenic
purpura during remission. Haematologica. 93:232–239. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Arya M, Anvari B, Romo GM, Cruz MA, Dong
JF, McIntire LV, Moake JL and López JA: Ultralarge multimers of von
willebrand factor form spontaneous high-strength bonds with the
platelet glycoprotein Ib-IX complex: Studies using optical
tweezers. Blood. 99:3971–3977. 2002. View Article : Google Scholar : PubMed/NCBI
|
